Equities research analysts expect AstraZeneca PLC (NASDAQ:AZN) to report $0.54 earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have provided estimates for AstraZeneca’s earnings. The lowest EPS estimate is $0.47 and the highest is $0.66. AstraZeneca reported earnings of $0.48 per share during the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The business is expected to report its next earnings results on Thursday, July 29th.
On average, analysts expect that AstraZeneca will report full-year earnings of $2.61 per share for the current financial year, with EPS estimates ranging from $2.42 to $2.83. For the next financial year, analysts forecast that the firm will post earnings of $3.24 per share, with EPS estimates ranging from $2.60 to $3.68. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover AstraZeneca.
AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, April 29th. The company reported $0.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.11. The firm had revenue of $7.32 billion for the quarter, compared to the consensus estimate of $7.15 billion. AstraZeneca had a net margin of 14.42% and a return on equity of 41.94%. The business’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.05 earnings per share.
Several equities research analysts have recently issued reports on the company. Berenberg Bank reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 9th. Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Monday, March 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, March 18th. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, March 23rd. Finally, UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, March 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $89.25.
AstraZeneca stock traded down $0.04 during mid-day trading on Monday, hitting $57.40. 7,252,813 shares of the company’s stock were exchanged, compared to its average volume of 7,905,120. The company has a current ratio of 0.87, a quick ratio of 0.67 and a debt-to-equity ratio of 1.21. The stock has a market cap of $150.65 billion, a P/E ratio of 37.76, a P/E/G ratio of 1.24 and a beta of 0.56. AstraZeneca has a 1-year low of $46.48 and a 1-year high of $64.94. The stock has a 50 day moving average of $52.29 and a two-hundred day moving average of $51.03.
Several institutional investors and hedge funds have recently modified their holdings of the company. Arkadios Wealth Advisors bought a new stake in AstraZeneca during the 4th quarter worth approximately $28,000. Hoover Financial Advisors Inc. bought a new stake in AstraZeneca during the 4th quarter worth approximately $30,000. Tsfg LLC grew its position in AstraZeneca by 67.4% during the 4th quarter. Tsfg LLC now owns 636 shares of the company’s stock worth $32,000 after acquiring an additional 256 shares during the last quarter. Concord Wealth Partners bought a new stake in AstraZeneca during the 4th quarter worth approximately $34,000. Finally, IronBridge Private Wealth LLC bought a new stake in AstraZeneca during the 4th quarter worth approximately $35,000. 14.47% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
See Also: Asset Allocation Models, Which is Right For You?
Get a free copy of the Zacks research report on AstraZeneca (AZN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com